[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610651":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":24,"studyPopulation":17,"armGroups":25,"interventions":32,"overallOfficials":38,"centralContacts":42,"locations":46,"responsibleParty":77,"collaborators":17,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":17,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":17,"enrollmentInfo":88,"targetDuration":17,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":49,"whyStopped":17,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Xencor, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Primary","Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)","Through Week 52",[14],{"measure":15,"description":16,"timeFrame":12},"Secondary","Serum concentration of plamotamab",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE","This is a Phase 1b study to determine the safety, tolerability, pharmacokinetic (PK), and pharmacodynamics (PD), and immunogenicity of plamotamab in adult participants with moderately to severely active RA. This is an open label dose optimization trial with approximately 68 participants assigned to different dose escalation cohorts.",[26],{"label":27,"type":28,"description":29,"interventionNames":30},"Dose Escalation","EXPERIMENTAL","Plamotamab administered SC",[31],"Biological: Plamotamab",[33],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":17},"BIOLOGICAL","Plamotamab","Biological",[27],[39],{"name":40,"affiliation":5,"role":41},"676-06 Study Information","STUDY_DIRECTOR",[43],{"name":40,"role":44,"phone":17,"phoneExt":17,"email":45},"CONTACT","676-Aiinfo@xencor.com",[47,59,68],{"facility":48,"status":49,"city":50,"state":17,"zip":17,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":17},"Xencor Investigative Site","RECRUITING","Tbilisi","Georgia","GE",{"type":54,"coordinates":55},"Point",[56,57],44.83412,41.69143,{"lat":57,"lon":56},{"facility":48,"status":49,"city":60,"state":17,"zip":17,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":67,"contacts":17},"Chisinau","Moldova","MD",{"type":54,"coordinates":64},[65,66],28.85938,47.00902,{"lat":66,"lon":65},{"facility":48,"status":49,"city":69,"state":17,"zip":17,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":17},"Auckland","New Zealand","NZ",{"type":54,"coordinates":73},[74,75],174.76349,-36.84853,{"lat":75,"lon":74},{"type":78,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100610651","phase-1-a-phase-1b-open-label-study-to-evaluate-safety-of-plamotamab-in-participants-with-rheumatoid-arthritis-100610651",false,"NCT07230353","A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis","A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis","Inclusion Criteria: Adult participants with moderately to severely active RA.\n\n* Documented diagnosis of RA and meeting the 2010 American College of Rheumatology\u002FEuropean Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening\n* Inadequate response to, loss of response to, or intolerance to available RA therapies.\n* Stable doses of RA medications prior to screening\n* Use of highly effective methods of contraception\n\nExclusion Criteria:\n\n* Major surgery within 12 weeks prior to screening or planned within 12 months after dosing\n* Recurrent infections or active clinically significant infection\n* Active or untreated latent tuberculosis\n* Cancer or history of cancer or lymphoproliferative disease within the previous 5 years\n* Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease\n\nNote: Additional, more specific inclusion\u002Fexclusion criteria are defined in the protocol.","ALL","18 Years",{"count":89,"type":90},68,"ESTIMATED","INTERVENTIONAL",[93],"PHASE1","The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.",[96],"Rheumatoid Arthritis",[98],"Rheumatoid Arthritis, Arthritis Rheumatoid, Arthritis","2026-07-31",{"date":101,"type":102},"2026-08-03","ACTUAL",{"date":104,"type":102},"2025-10-21",{"date":106,"type":90},"2028-06",{"name":5,"class":6},3]